India, Nov. 5 -- Gilead Sciences, Inc. (GILD) on Thursday announced positive detailed results from the Phase 3 IDEAL study, demonstrating that Livdelzi (seladelpar) helped achieve alkaline phosphatase (ALP) normalization in adults with primary biliary cholangitis (PBC) who had elevated ALP levels below the threshold typically studied in clinical trials.
At Week 52, 75.4% of participants treated with Livdelzi (49 of 65) achieved the ALP normalization composite endpoint, compared with 16.1% of those receiving placebo (5 of 31).
The endpoint required ALP levels at or below the upper limit of normal and at least a 15% reduction from baseline.
The treatment response was evident as early as one month, when 52.3% of Livdelzi-treated participant...